Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-951P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) family. U6 snRNA itself is a highly conserved, essential component of the spliceosomal complex, participating in pre-mRNA splicing in eukaryotes by forming dynamic RNA-RNA interactions during spliceosome assembly and activation. However, pseudogenes such as RNU6-951P do not encode functional snRNA or protein; instead, they are typically non-functional DNA sequences that may be transcribed into non-coding RNAs. Some pseudogene RNAs can influence cellular pathways by acting as competing endogenous RNAs (ceRNAs), miRNA sponges, or regulators of parental gene expression. There is no evidence that RNU6-951P is a receptor, enzyme, transporter, or actively involved in signaling or disease; it is not considered a therapeutic target. Its functional role, if any, would be restricted to possible RNA-mediated regulatory effects, and there is no direct disease association or drug interaction known for this specific pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 951, pseudogene (RNU6-951P).